In this video, Jordan Reynolds, MD, anatomic and molecular pathologist at Cleveland Clinic’s Robert J. Tomsich Pathology and Laboratory Medicine Institute, discusses how fluorescence in situ hybridization testing ultimately gave a patient with adenocarcinoma options for less toxic chemotherapy.
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Dr. Reynolds begins this three-minute video with an analysis of a slide obtained from an endobronchial ultrasound-guided fine needle aspiration. Watch as he demonstrates the diagnosis of lung cancer from small specimens: